Note the last paragraph above. The price started spiking when that report came out. Industry insiders agree on the importance of Vascepa.
"In regard to generics, Mr. Thero made some bold and declarative statements, including:
"We continue our work to convince managed-care plans that generic Lovaza will remain more expensive to them than Vascepa"
"generic Lovaza is not a typical generic in that it's more expensive and periodically in short supply"
"While Lovaza doesn't have the 96% EPA-only purity of Vascepa, its EPA plus DHA content is approximately 84%, such that it will be difficult to profitably manufacture and sell it at discounted price levels typical of other classes of generic drugs"
To use an analogy, I get the sense that EPA is much like gold in that the costs to explore, extract, and purify are more or less shared by all players in the space, which is why there are no generic gold producers. If Mr. Thero is correct in saying generics will remain more expensive than Vascepa, they will pose little to no threat to the company's marketing efforts should REDUCE-IT be successful.
In terms of the patent coverage, which generics would also have to navigate, Amarin scored what can only be described as a victory in its suit vs. AstraZeneca. In the end, the suit was dismissed as AstraZeneca played dead. Despite setting a previous launch date for 4Q2014, the company said it had no plans to market Epanova in 2014. It further added that Epanova's launch is not imminent and it would provide notice to Amarin prior to one.
Amarin's goal was to stop Epanova from launching and, for the time being, it succeeded. I think this speaks directly to the strength and value of its intellectual property and bodes well for the future.
Concerning the product which the IP is protecting, new data was presented at an American Heart Association meeting which continued to support Amarin's thesis that Vascepa will play a meaningful role in reducing cardiovascular events in its targeted patient population, including those receiving statin therapy."
Now you know the rest of the story
Avg Vol (3 month)3: 2,993,180
Avg Vol (10 day)3: 9,115,560
Shares Outstanding5: 45.67M
% Held by Insiders1: 7.79%
% Held by Institutions1: 61.20%
Shares Short (as of Mar 31, 2016)3: 18.12M
Short Ratio (as of Mar 31, 2016)3: 7.49
Short % of Float (as of Mar 31, 2016)3: 44.02%
Concerning Sarepta's drug candidate :
( check capitalized-sound familiar- money talks )
"More than 35 physicians and leading experts, who have seen some 5,000 Duchenne patients and hail from the likes of UCLA and Harvard, offered their opinion in a February letter to the FDA, not that the agency asked. The doctors say the FDA’s work includes “SCIENTIICALLY QUESTTIONL COMPARISONS" and even errors.
The boys are “clearly performing better than our collective clinical experience and the published literature would predict,” and the data show “substantial evidence of efficacy,” wrote the doctors. Accelerated approval and continuing further trials as the 2012 law prescribes, they concluded, “is the most ethical choice.”
Adding more weight to the decision is that eteplirsen can only treat a certain mutation of Duchenne, and a no from the FDA would scuttle iterations in the drug-development pipeline that might help more patients. Biotech companies working on treatments for other rare conditions are also watching. If a drug with no safety risks, a four-year record of effectiveness, and a strong legal and ethical basis can’t win approval, what can?
Sarepta, with 200-odd employees, may not have the resources for several more rounds with an agency that seems to enjoy issuing ominous reports and watching the company’s stock crater; Sarepta tanked 44% on Thursday when the FDA issued another unfavorable briefing ahead of Monday’s meeting. The stock fell more than 50% when the January report emerged. The result of this political control is fewer companies taking the risks that result in cures."
"Had this information been disclosed to plaintiffs and the public at large, her and her husband’s financial gain and net worth would have plummeted, since Dr. Margaret A. Hamburg’s husband, Peter F. Brown, reaped and continues to reap huge financial gain as a result of Renaissance Technologies, L.L.C.’s holdings of Johnson & Johnson stock,” according to the complaint.
Small cracks in the wall of resistance will eventually crumble that wall. Pressure is building slowly.
Thanks, I have learned more in the minutes it took to read your post than I have in the months I have spent here. Unfortunately, I enjoy squirting the ants here with a water pistol. I know it is childish, but they deserve it. You should go to the Amarin board on ihub for the exchange of information, it is quite inciteful and you will find several posters on yor intellectual level.